Our mission is to deliver smarter, safer, and more effective cancer treatments

We’ve assembled the right team to do what others couldn’t bring a new class of targeted cancer therapies to patients by pairing strong science with focused execution.

John Foglesong

Co-Founder & CEO

Read More

Sanket Mishra

Ph.D., Co-Founder & VP Research

Read More

Michael Rafferty

Ph.D., Head of Preclinical Development

Read More

Daniel L. Flynn

Ph.D., CSO & Board Member

Read More

Brian S. J. Blagg

Ph.D., Co-Founder & Board Observer

Read More

Patricia Martin

MBA, Board Observer

Read More

Stanley Zee

MS, Board Observer

Read More